CN105963294A - Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus - Google Patents

Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus Download PDF

Info

Publication number
CN105963294A
CN105963294A CN201610433543.1A CN201610433543A CN105963294A CN 105963294 A CN105963294 A CN 105963294A CN 201610433543 A CN201610433543 A CN 201610433543A CN 105963294 A CN105963294 A CN 105963294A
Authority
CN
China
Prior art keywords
indole
carbinol
radix
diindolylmethane
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610433543.1A
Other languages
Chinese (zh)
Inventor
张阳康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610433543.1A priority Critical patent/CN105963294A/en
Publication of CN105963294A publication Critical patent/CN105963294A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A61K36/068—Cordyceps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of biological medicine, in particular to an application of indole-3-carbinol, diindolylmethane, a derivative of indole-3-carbinol and a derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus and an ointment preparation prepared from indole-3-carbinol, diindolylmethane, a derivative of indole-3-carbinol and a derivative of diindolylmethane. The formula is simple, and it is avoided that a traditional preparing technology is complex; in addition, the components are reasonably mixed; due to the added indole-3-carbinol, the added diindolylmethane, the added derivative of indole-3-carbinol and the added derivative of diindolylmethane, lupus erythematosus can be effectively treated; due to the effect of cooperation with an assistant medicament, the good treatment effect on lupus erythematosus can be achieved; due to the effects of the indole-3-carbinol, the diindolylmethane, the derivative of indole-3-carbinol and the derivative of diindolylmethane, the effect of the treatment medicine is more durable, complex medicine replacing operation is avoided, the treatment effect on a patient can be improved greatly, the treatment burdens of a patient can be reduced, a patient can be well treated, and the good treatment effect is achieved.

Description

Indole -3- The application in preparation treatment lupus erythematosus medicine of methanol, di-indole methyl hydride and derivant thereof
Technical field
The present invention relates to pharmaceutical technology field, specially Indole-3-carbinol, di-indole methyl hydride and derivant thereof the application in preparation treatment lupus erythematosus medicine.
Background technology
Lupus erythematosus is a kind of agnogenic struvite connective tissue disease, occurs mainly in young women, but also involves child.
Lupus erythematosus is a spetrum disease, and one end of sick spectrum is discoid lupus erythematosus, and pathological changes is limited primarily to skin, mucosa；The other end is systemic lupus erythematosus (sle), allowance for bark outside skin, mucosa, often involve the internal organs such as kidney, cardiac muscle, liver, lung and nervous system, it is often accompanied by the General Symptomies such as heating, weak, arthralgia, and have a lot of autoantibody in blood, being likely due to the raising to the light-duty lupus erythematosus level of understanding, in world wide, the case load of report has the trend day by day increased in recent years.Lupus erythematosus has become commonly encountered diseases, and is increasingly paid attention to by each section doctor.
Lupus erythematosus belongs to autoimmune, and its cause of disease is failed to understand so far, it is considered that be many heredity.The mutual complicated effects such as inherited genetic factors, gonadal hormone and environmental factors cause Organism immunoregulation dysfunction, cause the generation of lupus erythematosus and continue, and make disease be difficult to alleviate.
The existing ingredient for external application for curing lupus erythematosus is complicated; it is higher that processing technology implements difficulty; and effectiveness comparison is poor; patient is when carrying out using medicine; would generally occur that medicine effect is inconspicuous and changes medicine phenomenon frequently, therapeutic effect is the best, it is impossible to well treat lupus erythematosus disease; and greatly enhance the cost of patient treatment, add the biggest burden to patient.
Summary of the invention
It is an object of the invention to provide the application in preparation treatment lupus erythematosus medicine of Indole-3-carbinol, di-indole methyl hydride and derivant thereof, with the problem solving to propose in above-mentioned background technology.
For achieving the above object, the present invention provides following technical scheme: Indole-3-carbinol, di-indole methyl hydride and derivant thereof are preparing the application treated in lupus erythematosus medicine.
Preferred: said preparation includes following components by weight percent: Indole-3-carbinol 3-6 part, di-indole methyl hydride 2-5 part, Indole-3-carbinol derivant 5-7 part, diindolylmethane derivative 4-7 part, assistant medicament 130-235 part and guaiazulene 1 part.
Preferred: described assistant medicament includes following components by weight percent: Cordyceps 3-6 part, Rhizoma Polygonati 4-7 part, Herba Houttuyniae 6-8 part, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 4-7 part, Cortex Moutan 2-4 part, Radix Salviae Miltiorrhizae 4-8 part, Hirudo 2-5 part, Colla Corii Asini 3-7 part, Semen Sinapis Albae 5-9 part, Radix Bupleuri 4-7 part, Cortex Cinnamomi 6-9 part, Radix Glycyrrhizae 4-8 part, Poria 7-9 part, Radix Scutellariae 4-5 part, Herba Dendrobii 2-6 part, water 70-130 part.
Preferred: this ointment formulation is prepared by following steps:
S1: weigh counterweight, takes institute's raw material in need according to certain component ratio weighing；
S2: fresh Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii are cleaned free from admixture, by the juice of milling and extracting Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii, by the way of centrifugal filtration, obtains pure liquid；
S3: by powdered for Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae individually micronizing；
S4: successively respectively the powder of Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae is filtered by the screen cloth of 200 mesh, 300 mesh and 400 mesh, obtain fine medicated powder；
S5: the fine medicated powder, liquid juice and the water that obtain are mixed, obtains mixed liquid；
S6: transferring to, in heater, heat by mixed liquid, the temperature of firing equipment controls between 100-103 degree Celsius, until material liquid seethes with excitement, and continue to keep heating, need persistence to stir in heating process, after having heated, by liquid natural cooling, obtain assistant medicament；
S7: assistant medicament, Indole-3-carbinol, di-indole methyl hydride, Indole-3-carbinol derivant and diindolylmethane derivative are added in electromagnetic stirring equipment and heat, continuously stirred and heating 5-10 minute, heating is stopped after liquid is ointment shape, and it is added thereto to guaiazulene, more continuously stirred 4-7 minute；
S8: by the soft paste medicament obtained by packing after vacreation, so far this ointment formulation completes.
Compared with prior art, the invention has the beneficial effects as follows: the formula of the present invention is simple, avoid the situation of the reparation technology complexity that conventional art exists, and each component arranges rationally, by the Indole-3-carbinol added, di-indole methyl hydride and derivant thereof can effectively treat lupus erythematosus, by the mating reaction with assistant medicament, lupus erythematosus can be played good therapeutical effect, and pass through Indole-3-carbinol, di-indole methyl hydride and the effect of derivant thereof, the drug effect making medicine is the most lasting, not only avoid loaded down with trivial details operation of changing dressings, and can largely improve the therapeutic effect of patient, reduce the treatment burden of patient, enable the patient to well be treated, there is good therapeutic effect.
Detailed description of the invention
It is clearly and completely described below in conjunction with the technical scheme in the embodiment of the present invention, it is clear that described embodiment is only a part of embodiment of the present invention rather than whole embodiments.Based on the embodiment in the present invention, the every other embodiment that those of ordinary skill in the art are obtained under not making creative work premise, broadly fall into the scope of protection of the invention.
Embodiment one
The present invention provides a kind of technical scheme: Indole-3-carbinol, di-indole methyl hydride and derivant thereof are preparing the application treated in lupus erythematosus medicine.
The ointment formulation of Indole-3-carbinol, di-indole methyl hydride and derivant thereof, said preparation includes following components by weight percent: Indole-3-carbinol 3 parts, di-indole methyl hydride 2 parts, Indole-3-carbinol derivant 5 parts, diindolylmethane derivative 4 parts, assistant medicament 130 parts and guaiazulene 1 part.
Described assistant medicament includes following components by weight percent: Cordyceps 3 parts, Rhizoma Polygonati 4 parts, Herba Houttuyniae 6 parts, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 4 parts, Cortex Moutan 2 parts, Radix Salviae Miltiorrhizae 4 parts, Hirudo 2 parts, 3 parts of Colla Corii Asini, Semen Sinapis Albae 5 parts, Radix Bupleuri 4 parts, Cortex Cinnamomi 6 parts, 4 parts of Radix Glycyrrhizae, 7 parts of Poria, Radix Scutellariae 4 parts, Herba Dendrobii 2 parts, 70 parts of water.
This ointment formulation is prepared by following steps:
S1: weigh counterweight, takes institute's raw material in need according to certain component ratio weighing；
S2: fresh Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii are cleaned free from admixture, by the juice of milling and extracting Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii, by the way of centrifugal filtration, obtains pure liquid；
S3: by powdered for Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae individually micronizing；
S4: successively respectively the powder of Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae is filtered by the screen cloth of 200 mesh, 300 mesh and 400 mesh, obtain fine medicated powder；
S5: the fine medicated powder, liquid juice and the water that obtain are mixed, obtains mixed liquid；
S6: transfer to, in heater, heat by mixed liquid, the temperature of firing equipment controls at 102 degrees Celsius, until material liquid seethes with excitement, and continue to keep heating, need persistence to stir in heating process, after having heated, by liquid natural cooling, obtain assistant medicament；
S7: assistant medicament, Indole-3-carbinol, di-indole methyl hydride, Indole-3-carbinol derivant and diindolylmethane derivative are added in electromagnetic stirring equipment and heat, continuously stirred and heating 8 minutes, heating is stopped after liquid is ointment shape, and it is added thereto to guaiazulene, more continuously stirred 5 minutes；
S8: by the soft paste medicament obtained by packing after vacreation, so far this ointment formulation completes.
Embodiment two
The present invention provides a kind of technical scheme: Indole-3-carbinol, di-indole methyl hydride and derivant thereof are preparing the application treated in lupus erythematosus medicine.
The ointment formulation of Indole-3-carbinol, di-indole methyl hydride and derivant thereof, said preparation includes following components by weight percent: Indole-3-carbinol 4 parts, di-indole methyl hydride 3 parts, Indole-3-carbinol derivant 6 parts, diindolylmethane derivative 5 parts, assistant medicament 155 parts and guaiazulene 1 part.
Described assistant medicament includes following components by weight percent: Cordyceps 4 parts, Rhizoma Polygonati 5 parts, Herba Houttuyniae 7 parts, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 5 parts, Cortex Moutan 3 parts, Radix Salviae Miltiorrhizae 5 parts, Hirudo 3 parts, 4 parts of Colla Corii Asini, Semen Sinapis Albae 6 parts, Radix Bupleuri 5 parts, Cortex Cinnamomi 7 parts, 5 parts of Radix Glycyrrhizae, 8 parts of Poria, Radix Scutellariae 5 parts, Herba Dendrobii 3 parts, 80 parts of water.
This ointment formulation is prepared by following steps:
S1: weigh counterweight, takes institute's raw material in need according to certain component ratio weighing；
S2: fresh Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii are cleaned free from admixture, by the juice of milling and extracting Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii, by the way of centrifugal filtration, obtains pure liquid；
S3: by powdered for Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae individually micronizing；
S4: successively respectively the powder of Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae is filtered by the screen cloth of 200 mesh, 300 mesh and 400 mesh, obtain fine medicated powder；
S5: the fine medicated powder, liquid juice and the water that obtain are mixed, obtains mixed liquid；
S6: transfer to, in heater, heat by mixed liquid, the temperature of firing equipment controls at 102 degrees Celsius, until material liquid seethes with excitement, and continue to keep heating, need persistence to stir in heating process, after having heated, by liquid natural cooling, obtain assistant medicament；
S7: assistant medicament, Indole-3-carbinol, di-indole methyl hydride, Indole-3-carbinol derivant and diindolylmethane derivative are added in electromagnetic stirring equipment and heat, continuously stirred and heating 9 minutes, heating is stopped after liquid is ointment shape, and it is added thereto to guaiazulene, more continuously stirred 6 minutes；
S8: by the soft paste medicament obtained by packing after vacreation, so far this ointment formulation completes.
Embodiment three
The present invention provides a kind of technical scheme: Indole-3-carbinol, di-indole methyl hydride and derivant thereof are preparing the application treated in lupus erythematosus medicine.
The ointment formulation of Indole-3-carbinol, di-indole methyl hydride and derivant thereof, said preparation includes following components by weight percent: Indole-3-carbinol 6 parts, di-indole methyl hydride 5 parts, Indole-3-carbinol derivant 7 parts, diindolylmethane derivative 7 parts, assistant medicament 235 parts and guaiazulene 1 part.
Described assistant medicament includes following components by weight percent: Cordyceps 6 parts, Rhizoma Polygonati 7 parts, Herba Houttuyniae 8 parts, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 7 parts, Cortex Moutan 4 parts, Radix Salviae Miltiorrhizae 8 parts, Hirudo 5 parts, 7 parts of Colla Corii Asini, Semen Sinapis Albae 9 parts, Radix Bupleuri 7 parts, Cortex Cinnamomi 9 parts, 8 parts of Radix Glycyrrhizae, 9 parts of Poria, Radix Scutellariae 5 parts, Herba Dendrobii 6 parts, 130 parts of water.
This ointment formulation is prepared by following steps:
S1: weigh counterweight, takes institute's raw material in need according to certain component ratio weighing；
S2: fresh Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii are cleaned free from admixture, by the juice of milling and extracting Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii, by the way of centrifugal filtration, obtains pure liquid；
S3: by powdered for Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae individually micronizing；
S4: successively respectively the powder of Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae is filtered by the screen cloth of 200 mesh, 300 mesh and 400 mesh, obtain fine medicated powder；
S5: the fine medicated powder, liquid juice and the water that obtain are mixed, obtains mixed liquid；
S6: transfer to, in heater, heat by mixed liquid, the temperature of firing equipment controls between 103 degrees Celsius, until material liquid seethes with excitement, and continue to keep heating, need persistence to stir in heating process, after having heated, by liquid natural cooling, obtain assistant medicament；
S7: assistant medicament, Indole-3-carbinol, di-indole methyl hydride, Indole-3-carbinol derivant and diindolylmethane derivative are added in electromagnetic stirring equipment and heat, continuously stirred and heating 10 minutes, heating is stopped after liquid is ointment shape, and it is added thereto to guaiazulene, more continuously stirred 7 minutes；
S8: by the soft paste medicament obtained by packing after vacreation, so far this ointment formulation completes.
nullFound by the contrast test of the embodiments of above-mentioned three groups，Implement row for three groups and all lupus erythematosus can be had good therapeutic effect，The effect that can make medicine is the most lasting，Action effect is more preferable，The lupus erythematosus condition of illness that can make patient is well alleviated，Wherein implement the best results of row three，Therefore reach a conclusion，The formula of the present invention is the simplest，And coordinate scientific and reasonable between each component，Pass through Indole-3-carbinol、Di-indole methyl hydride and derivant thereof can be good at reducing the harm that the body of patient is caused by lupus erythematosus，Spreading of effective control lupus erythematosus condition of illness，Indole-3-carbinol、The mating reaction of di-indole methyl hydride and derivant thereof and assistant medicament，The lupus erythematosus condition of illness that can make patient is eased and treats，Stimulate skin regeneration，And the advantage that the present invention has lasting medicine，Pass through Indole-3-carbinol、The effect of di-indole methyl hydride and derivant thereof makes the therapeutic effect of medicine give full play to，Solve conventional medicament，The property of medicine distributes problem that is not thorough and that frequently change medicine，The most economically and efficiently medicine is provided for patient.
Although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, being appreciated that and these embodiments can carry out multiple change without departing from the principles and spirit of the present invention, revise, replace and modification, the scope of the present invention be defined by the appended.

Claims (4)

1. Indole-3-carbinol, di-indole methyl hydride and derivant thereof the application in preparation treatment lupus erythematosus medicine.
The ointment formulation of Indole-3-carbinol the most according to claim 1, di-indole methyl hydride and derivant thereof, it is characterised in that: said preparation includes following components by weight percent: Indole-3-carbinol 3-6 part, di-indole methyl hydride 2-5 part, Indole-3-carbinol derivant 5-7 part, diindolylmethane derivative 4-7 part, assistant medicament 130-235 part and guaiazulene 1 part.
A kind of Indole-3-carbinol the most according to claim 2, di-indole methyl hydride and the ointment formulation of derivant thereof, it is characterised in that: described assistant medicament includes following components by weight percent: Cordyceps 3-6 part, Rhizoma Polygonati 4-7 part, Herba Houttuyniae 6-8 part, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 4-7 part, Cortex Moutan 2-4 part, Radix Salviae Miltiorrhizae 4-8 part, Hirudo 2-5 part, Colla Corii Asini 3-7 part, Semen Sinapis Albae 5-9 part, Radix Bupleuri 4-7 part, Cortex Cinnamomi 6-9 part, Radix Glycyrrhizae 4-8 part, Poria 7-9 part, Radix Scutellariae 4-5 part, Herba Dendrobii 2-6 part, water 70-130 part.
4. according to the ointment formulation of a kind of Indole-3-carbinol, di-indole methyl hydride and derivant thereof described in Claims 2 or 3, it is characterised in that: this ointment formulation is prepared by following steps:
S1: weigh counterweight, takes institute's raw material in need according to certain component ratio weighing；
S2: fresh Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii are cleaned free from admixture, by the juice of milling and extracting Herba Houttuyniae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Radix Glycyrrhizae and Herba Dendrobii, by the way of centrifugal filtration, obtains pure liquid；
S3: by powdered for Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae individually micronizing；
S4: successively respectively the powder of Cordyceps, Rhizoma Polygonati, Cortex Moutan, Radix Salviae Miltiorrhizae, Hirudo, Colla Corii Asini, Semen Sinapis Albae, Radix Bupleuri, Cortex Cinnamomi, Poria and Radix Scutellariae is filtered by the screen cloth of 200 mesh, 300 mesh and 400 mesh, obtain fine medicated powder；
S5: the fine medicated powder, liquid juice and the water that obtain are mixed, obtains mixed liquid；
S6: transferring to, in heater, heat by mixed liquid, the temperature of firing equipment controls between 100-103 degree Celsius, until material liquid seethes with excitement, and continue to keep heating, need persistence to stir in heating process, after having heated, by liquid natural cooling, obtain assistant medicament；
S7: assistant medicament, Indole-3-carbinol, di-indole methyl hydride, Indole-3-carbinol derivant and diindolylmethane derivative are added in electromagnetic stirring equipment and heat, continuously stirred and heating 5-10 minute, heating is stopped after liquid is ointment shape, and it is added thereto to guaiazulene, more continuously stirred 4-7 minute；
S8: by the soft paste medicament obtained by packing after vacreation, so far this ointment formulation completes.
CN201610433543.1A 2016-06-18 2016-06-18 Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus Pending CN105963294A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610433543.1A CN105963294A (en) 2016-06-18 2016-06-18 Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610433543.1A CN105963294A (en) 2016-06-18 2016-06-18 Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus

Publications (1)

Publication Number Publication Date
CN105963294A true CN105963294A (en) 2016-09-28

Family

ID=57021316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610433543.1A Pending CN105963294A (en) 2016-06-18 2016-06-18 Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus

Country Status (1)

Country Link
CN (1) CN105963294A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101940568A (en) * 2010-08-17 2011-01-12 合肥博太医药生物技术发展有限公司 Application of indole-3-methanol, diindolylmethane and derivatives thereof in preparing medicament for treating cardiac failure caused by anthracycline
CN102335168A (en) * 2011-10-25 2012-02-01 合肥博太医药生物技术发展有限公司 Application of indole-3-carbinol, diindolyl methane and derivatives thereof in preparation of medicaments for treating osteoporosis
CN102370638A (en) * 2010-08-20 2012-03-14 南京大学 Application of 3,3'-diindolylmethane and 3,3'-diindolylmethane derivatives in preparation of drugs for treating liver diseases
CN104383097A (en) * 2014-11-27 2015-03-04 黄琴 Traditional Chinese medicine for treating lupus erythematosus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101940568A (en) * 2010-08-17 2011-01-12 合肥博太医药生物技术发展有限公司 Application of indole-3-methanol, diindolylmethane and derivatives thereof in preparing medicament for treating cardiac failure caused by anthracycline
CN102370638A (en) * 2010-08-20 2012-03-14 南京大学 Application of 3,3'-diindolylmethane and 3,3'-diindolylmethane derivatives in preparation of drugs for treating liver diseases
CN102335168A (en) * 2011-10-25 2012-02-01 合肥博太医药生物技术发展有限公司 Application of indole-3-carbinol, diindolyl methane and derivatives thereof in preparation of medicaments for treating osteoporosis
CN104383097A (en) * 2014-11-27 2015-03-04 黄琴 Traditional Chinese medicine for treating lupus erythematosus

Similar Documents

Publication Publication Date Title
CN101062361A (en) Chinese traditional medicine for treating dermatosis and its preparation method
CN100528211C (en) Traditional Chinese medicine for treating tumor
CN104208163B (en) It is a kind of improve animal immunizing power Chinese veterinary medicinal composition, using and preparation method thereof
CN102813850B (en) Traditional Chinese medicine composition for preventing and treating poultry coccidiosis and preparation method of traditional Chinese medicine composition
CN101297871A (en) Chinese medicinal composition for preventing and controlling enteritis of birds
CN102657839B (en) Traditional Chinese medicine capsule for treating coronary heart disease
CN105963294A (en) Application of indole-3-carbinol, diindolylmethane, derivative of indole-3-carbinol and derivative of diindolylmethane to preparing of medicine for treating lupus erythematosus
CN102670863B (en) Compound propolis composition for treating acariasis of domestic animal and preparation method thereof
CN103083632B (en) Traditional Chinese medicine for treating recurrent aphthae
CN101380368A (en) Traditional Chinese medicine composition for treating birds enteritis and dysentery
CN1104906A (en) "Futongning" health bag
CN1250273C (en) Venom capsule for treating brain cancer
CN1899387A (en) Method for preventing and treating child convulsion and its preparing method
CN1927282A (en) Preparation for treating arthritis and preparation method thereof
CN1686497A (en) Chinese medicinal preparation for treating sexual dysfunction, menoxenia, aciesis and developing immunity
CN1298379C (en) Medicine for curing malignant tumors of carcinoma of prostate, liver cancer and sarcoma
CN102406740B (en) Pure Chinese traditional medicine composition for treating poultry tissues trichomoniasis and its preparation method
CN102671122B (en) Compound pure Chinese medicinal composition for treating livestock gastric-enteritis and preparation method thereof
CN1166379C (en) Medicine for treating kidney disease and method for preparing same
CN1281252C (en) Medicinal composition for treating urinary lithiasis and its preparing method
CN105535138A (en) Traditional Chinese medicine preparation for treating hepatic fibrosis and preparation method thereof
CN106109803A (en) A kind of for diabetic foot care medicinal liquid
CN105687600A (en) Traditional Chinese medicine composition for treating climacteric syndrome, as well as preparation method and application thereof
CN105687365A (en) Traditional Chinese medicine composition for treating polymyositis and preparation method and application of traditional Chinese medicine composition for treating polymyositis
CN104474248A (en) Traditional Chinese medicinal composition for treating acute conjunctivitis and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160928